Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bispecific antibodies
Biotech
Ollin eyes phase 3 after topping Vabysmo in early-stage trial
Given the findings, the Texas-based biotech is now planning to launch global phase 3 studies this year.
Gabrielle Masson
Jan 8, 2026 3:20pm
J&J, Google venture arms line up to back EpiBiologics' series B
Jan 8, 2026 9:05am
Sanofi's 2nd autoimmune pact with AI biotech could reach $2.5B
Jan 5, 2026 7:30am
J&J junks $1.2B eczema therapy while Genmab drops cancer drug
Jan 2, 2026 9:05am
Windward pens $700M deal for Qyuns' immunology bispecific
Dec 22, 2025 7:40am
Fierce Pharma
ASH: J&J pressures CAR-T with Tecvayli combo in 2L myeloma
Dec 9, 2025 7:30am
